Virtus LifeSci Valuation

Virtus LifeSci Biotech Clinical Trls ETF -- USA Etf  

USD 31.33  0.47  1.52%

Virtus LifeSci Biotech has current Real Value of $31.66 per share. The regular price of the etf is $31.33. At this time the etf appears to be fairly valued. Macroaxis measures value of Virtus LifeSci Biotech from inspecting the etf fundamentals such as Number of Employees of 347, Net Asset of 72.06M and Price to Earning of 39.87times as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
 Time Horizon     30 Days    Login   to change
Virtus LifeSci Biotech Clinical Trls ETF is the top ETF in one year return as compared to similar ETFs. It is rated below average in price to book as compared to similar ETFs fabricating about  0.04  of Price to Book per One Year Return. The ratio of One Year Return to Price to Book for Virtus LifeSci Biotech Clinical Trls ETF is roughly  24.53 

Current Market Valuation

Virtus LifeSci Biotech Valuation Boundaries
Fairly Valued
April 26, 2018
31.33
Market Value
31.66
Real Value
Target Price Odds
 Above  Below  
38.71
Upside
Virtus LifeSci is not too volatile asset. Calculation of real value of Virtus LifeSci Biotech is based on 2 months time horizon. Increasing Virtus LifeSci Biotech time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Net Asset

Virtus LifeSci Net Asset Analysis
Virtus LifeSci Biotech Clinical Trls ETF is rated below average in net asset as compared to similar ETFs. Total Asset Under Management (AUM) of Sector category is currently estimated at about 157.37 Billion. Virtus LifeSci adds roughly 72.06 Million in net asset claiming only tiny portion of equities under Sector ETF category.
Check also Trending Equities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.